LONDON, UK / ACCESSWIRE / July 11, 2018 / Active-Investors has a free review on AbbVie Inc. (NYSE: ABBV) following the Company's announcement that it will begin trading ex-dividend on July 12, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on July 11, 2018. Active-Investors has initiated due-diligence on this dividend stock. Register with us for more free research including the one on ABBV:

www.active-investors.com/registration-sg/?symbol=ABBV

If your portfolio includes dividend stocks, you have come to the right place for timely information. All you need to do is sign up for your free membership at:

www.active-investors.com/registration-sg

Dividend Declared

On June 14, 2018, AbbVie's Board of Directors declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable on August 15, 2018, to stockholders of record at the close of business on July 13, 2018.

AbbVie's indicated dividend represents a yield of 3.96%, which is more than five times higher than the average dividend yield of 0.66% for the Healthcare sector. Since the Company's inception in 2013, AbbVie has increased its dividend by 140%.

Dividend Insights

AbbVie has a dividend payout ratio of 49.2%, which denotes that the Company spends approximately $0.49 for dividend distribution out of every $1.00 earned. The dividend payout ratio reflects how much amount a company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

As per analysts' estimates, AbbVie is forecasted to report earnings of 8.93 per share for the next year, which is more than double compared to the Company's annualized dividend payout of $3.84 per share.

As of March 31, 2018, AbbVie's cash and cash equivalents totaled $9.01 billion compared to $9.30 billion as on December 31, 2017. For the three months ended March 31, 2018, the Company's cash from operating activities were $2.65 billion compared to $2.10 billion for the year earlier corresponding quarter. The Company's strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain the dividend distribution for a long period.

Recent Development for AbbVie

On June 25, 2018, AbbVie announced that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental New Drug Application (sNDA) for IMBRUVICA® in combination with rituximab as a new treatment option for Waldenström's macroglobulinemia (WM), a rare and incurable form of blood cancer. As per the press release, there are approximately 2,800 new cases of WM in the US every year.

If approved, the sNDA would expand the prescribing information of IMBRUVICA in WM beyond its current approved use as a single agent for all lines of therapy to include combination use with rituximab. As a single-agent therapy, IMBRUVICA is the first and only FDA-approved treatment available for patients with WM.

About AbbVie Inc.

AbbVie is a global, research-driven biopharmaceutical Company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The Company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology, and neuroscience.

Stock Performance Snapshot

July 10, 2018 - At Tuesday's closing bell, AbbVie's stock rose 1.85%, ending the trading session at $98.84.

Volume traded for the day: 5.07 million shares.

Stock performance in the previous three-month period - up 5.58%; past twelve-month period - up 37.60%; and year-to-date - up 2.20%

After yesterday's close, AbbVie's market cap was at $157.25 billion.

Price to Earnings (P/E) ratio was at 15.89.

The stock has a dividend yield of 3.89%.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

SOURCE: Active-Investors